Key result
Among 85 small blue round cell tumors, 7 harbored FUS gene rearrangements, highlighting the need for additional molecular testing beyond standard EWSR1 FISH assays.
Observational (n=85)
Relying solely on EWSR1 FISH assay for Ewing sarcoma diagnosis can miss EWSR1-ERG fusions, highlighting the need for additional molecular testing like ERG FISH or NGS in classic cases.
Answers are grounded in this paper and cite their sources.
Relying solely on EWSR1 FISH may miss FUS-rearranged tumors; leaves open optimal testing algorithms in small blue round cell tumors.
The genetics of Ewing sarcoma (ES) are characterized by a canonical fusion involving EWSR1 gene and a member of the ETS family of transcription factors, such as FLI1 and ERG. In fact, ERG gene rearrangements represent the second most common molecular alteration, with EWSR1-ERG being identified in 5-10% of cases, while only a handful of reports document a FUS-ERG fusion. In this study, we focus on ES with ERG gene abnormalities, specifically to investigate the prevalence and clinicopathologic features of FUS-ERG fusions in a large cohort of small blue round cell tumors (SBRCTs) and compare to the eight reported FUS-positive ES. Among the 85 SBRCTs tested, seven (8.2%) cases harbored FUS gene rearrangements; six fused to ERG and one with FEV. During this investigation we came across a number of ERG-rearranged ES lacking both EWSR1 and FUS abnormalities by FISH. In one case, RNA sequencing identified an EWSR1-ERG transcript despite the negative EWSR1 rearrangements by FISH. Additional 3-color FISH fusion assay demonstrated the fusion of EWSR1 and ERG signals in all four cases negative for break-apart EWSR1 FISH. These results emphasize a potential pitfall of relying on EWSR1 FISH assay alone for diagnosis of ES. In cases with classic morphology and/or strong CD99 and ERG immunoreactivity, additional molecular testing should be applied, such as ERG FISH or RT-PCR/next generation sequencing, for a more definitive diagnosis. Although our study group is small, there were no differences noted between the clinical, morphologic features and immunoprofile of the different subsets of ERG-rearranged SBRCTs.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2015) conducted an observational in Small blue round cell tumors (SBRCTs) (n=85). FUS and ERG gene rearrangements was evaluated on Prevalence of FUS gene rearrangements. Among 85 small blue round cell tumors, 7 harbored FUS gene rearrangements, highlighting the need for additional molecular testing beyond standard EWSR1 FISH assays.
Synapse has enriched 10 related papers. Consider them for comparative context: